Preclinical development of Alimta (Pemetrexed, LY231514), a multitargeted antifolate.
Schultz
Richard M
RM
Division of Cancer Research, Lilly Research Laboratories, Lilly Corporate Center, Indianapolis, IN 46285, USA. Rick_1252@msn.com
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001692:Biological Transport; D019008:Drug Resistance, Neoplasm; D005493:Folic Acid Antagonists / Q000627:therapeutic use*; D005971:Glutamates / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use* / Q000633:toxicity; D006147:Guanine / Q000031:analogs & derivatives* / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use / Q000633:toxicity; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy*; D000068437:Pemetrexed; D011687:Purines / Q000037:antagonists & inhibitors; D013940:Thymidylate Synthase / Q000037:antagonists & inhibitors
D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D005971:Glutamates; D011687:Purines; D000068437:Pemetrexed; D006147:Guanine; D013940:Thymidylate Synthase; C030985:purine